PORTLAND, Ore., June 24, 2014 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"), an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced the appointment of global sales and marketing expert Scott Ashworth to the position of executive vice president of global sales.
"Scott's addition to our executive sales team is timely as we build our sales and marketing efforts for our U.S. FDA cleared product FloChec® that allows healthcare providers to measure arterial blood flow in the extremities and assess patients' vascular condition," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler. "We are committed to rapidly growing the sales of FloChec and further advancing the development and commercialization strategies of our future patented products."
Paul Scott, chief sales officer, added, "Scott has extensive experience in leading direct sales organizations and in building the capacities and processes necessary to drive sales growth on a global scale. His strong sales and marketing expertise in medical devices and proven track record in increasing sales momentum, will allow him to hit the ground running in driving sales for FloChec and Semler's future products."
Prior to joining Semler, Mr. Ashworth served as the executive vice president, global sales at Cutera, Inc., where he led the global sales organization in over 40 countries and redefined the structure, strategy and vision of the sales team to improve culture and drive market share growth. From 2012 to 2013, Mr. Ashworth served as the senior vice president, global sales at Avinger, Inc., where he built and managed a global sales organization of more than 50 team members. Prior to that, Mr. Ashworth served as the vice president, global sales and marketing at Heartflow, Inc., from 2011 to 2012, where he built the foundation for commercialization, including a global distribution partnership with General Electric, and hired a world-class team. Mr. Ashworth also held multiple senior sales executive
positions at Siemens Healthcare, Ultrasound Division (formerly Acuson), from 1997 to 2011, the most recent one being vice president, worldwide sales and service where he was responsible for $800 million in revenue across global sales and service operations. At Hewlett-Packard - Medical Products Group, Mr. Ashworth held the position of business development manager, Asia Pacific, from 1995 to 1997, where he managed and directed all corporate sales and marketing efforts across the Asia Pacific region. He holds a bachelor of arts degree in economic theory from UCLA in Los Angeles.
About Semler Scientific, Inc.:
Semler Scientific, Inc. is an emerging medical risk-assessment company. Its mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services. Semler's first patented and U.S. Food and Drug Administration, or FDA, cleared product, is FloChec®. FloChec® is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a useful tool for internists and primary care physicians for whom it was previously impractical to conduct blood flow measurements. FloChec® received FDA 510(k) clearance in February
2010, Semler began Beta testing in the third quarter of 2010, and Semler began commercially leasing FloChec® in January 2011. Semler closed the initial public offering of its common stock on February 26, 2014 and its common stock is now listed on the NASDAQ Capital Market under the ticker symbol "SMLR." Additional information about Semler can be found at www.semlerscientific.com.
Susan A. Noonan
S.A. Noonan Communications
212 966 3650
SOURCE Semler Scientific, Inc.